Antibiotic prophylaxis for patients with liver cirrhosis and upper gastrointestinal hemorrhage: Is there evidence for its use?;Antibiotikaprofylakse til levercirrosepatienter med øvre gastrointestinal blødning: Er der evidens for anvendelse?

Ugeskrift for Laeger

Volumn 167, Issue 7, 2005, Pages 735-739

  Kofoed, Kristian ^a,b   Kronborg, Gitte ^b  

^a Infektionsmedicinsk Afdeling ^*  (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEFAZOLIN; CEFOTAXIME; CEFTRIAXONE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; GENTAMICIN; NORFLOXACIN; NYSTATIN; OFLOXACIN; PLACEBO; VANCOMYCIN;

ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTION; CLINICAL TRIAL; HIGH RISK PATIENT; HUMAN; LIVER CIRRHOSIS; META ANALYSIS; MORTALITY; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UPPER GASTROINTESTINAL BLEEDING;

EID: 14144256269     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Blaise M, Pateron D, Trinchet JC et al. Systemic antibiotic therapy prevents bacterial infection in cirrhotic patients with gastrointestinal hemorrhage. Hepatology 19941;20:34-8.
2. Hsieh WJ, Lin HC, Hwang SJ et al. The effect of ciprofloxacin in the prevention of bacterial infection in patients with cirrhosis after upper gastrointestinal bleeding. Am J Gastroenterol 1998;93:962-6.
3. Lin YT, Lo GH, Lai KH et al. Prophylactic antibiotics in cirrhotics with upper gastrointestinal hemorrhage: a prospective, controlled trial. Zhonghua Yi Xue Za Zhi 2002;65:365-71.
4. Pauwels A, Mostefa-Kara N, Debenes B et al. Systemic antibiotic prophylaxis after gastrointestinal hemorrhage in cirrhotic patients with a high risk of infection. Hepatology 1996;24:802-6.
5. Rimola A, Bory F, Teres J et al. Oral, nonabsorbable antibiotics prevent infection in cirrhotics with gastrointestinal hemorrhage. Hepatology 1985;5: 463-7.
6. Soriano G, Guarner C, Tomas A et al. Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. Gastroenterology 1992;103: 1267-72.
7. Goulis J, Armonis A, Patch D et al. Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology 1998;27:1207-12.
8. Borzio M, Salerno F, Piantoni L et al. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis 2001; 33:41-8.
9. Vivas S, Rodriguez M, Palacio MA et al. Presence of bacterial infection in bleeding cirrhotic patients is independently associated with early mortality and failure to control bleeding. Dig Dis Sci 2001;46:2752-7.
10. Spanish Group for the Study of Bacterial Infections in Cirrhosis. Norfloxacin versus ofloxacin in the prophylaxis of infection in cirrhotic patients with gastrointestinal hemorrhage [abstract]. J Hepatol 1998;28(suppl 1):80.
11. Zacharof A, Petrogiannopoulos C, Flevaris C et al. Ciprofloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage [abstract]. Gut 1997;41(suppl 3):A189.
12. Bernard B, Grange JD, Khac EN et al. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 1999;29:1655-61.
13. Soares-Weiser K, Brezis M, Tur-Kaspa R et al. Antibiotic prophylaxis of bacterial infections in cirrhotic inpatients: a meta-analysis of randomized controlled trials. Scand J Gastroenterol 2003;38:193-200.
14. Rolando N, Gimson A, Philpott-Howard J et al. Infectious sequelae after endoscopic sclerotherapy of oesophageal varices: role of antibiotic prophylaxis. J Hepatol 1993;18:290-4.
15. Sabat M, Kolle L, Soriano G et al. Parenteral antibiotic prophylaxis of bacterial infections does not improve cost-efficacy of oral norfloxacin in cirrhotic patients with gastrointestinal bleeding. Am J Gastroenterol 1998;93:2457-62.
16. Gulberg V, Deibert P, Ochs A et al. Prevention of infectious complications after ter transjugular intrahepatic portosystemic shunt in cirrhotic patients with a single dose of ceftriaxone. Hepatogastroenterology 1999;46:1126-30.
17. Selby WS, Norton ID, Pokorny CS et al. Bacteremia and bacterascites after endoscopic sclerotherapy for bleeding esophageal varices and prevention by intravenous cefotaxime: a randomized trial. Gastrointest Endosc 1994;40: 680-4.
18. Deschenes M, Villeneuve JP. Risk factors for the development of bacterial infections in hospitalized patients with cirrhosis. Am J Gastroenterol 1999; 94:2193-7.
19. Bergan T, Delin C, Johansen S et al. Pharmacokinetics of ciprofloxacin and effect of repeated dosage on salivary and fecal microflora. Antimicrob Agents Chemother 1986;29:298-302.
20. Nord CE, Heimdahl A, Kager L. Antimicrobial induced alterations of the human oropharyngeal and intestinal microflora. Scand J Infect Dis Suppl 1986;49:64-72. Review.
21. Edlund C, Nord CE. Suppression of the oropharyngeal and gastrointestinal microflora by ciprofloxacin: microbiological and clinical consequences. Scand J Infect Dis Suppl 1989;60:98-103. Review.
22. Nord CE. Effect of quinolones on the human intestinal microflora. Drugs 1995;49(suppl 2):81-5. Review.
23. Edlund C, Nord CE. Effect of quinolones on intestinal ecology. Drugs 1999; 58 (suppl 2):65-70. Review.
24. Bernard B, Cadranel JF, Valla D et al. Prognostic significance of bacterial infection in bleeding cirrhotic patients: a prospective study. Gastroenterology 1995;108:1828-34.